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INTRODUCTION
The emergence of glycopeptide intermediate Staphylo-
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coccus aureus (GISA) has caused serious concerns about
the antimicrobial treatment of S. aureus endocarditis.
Moore et al. (1) reported vancomycin treatment failure
associated with GISA in a patient with endocarditis and
in the rabbit model of endocarditis. Pavie et al.(2) re-
ported teicoplanin was approximately 100-fold less active
than the standard dose of vancomycin against the GISA
strain and selected for the emergence of more resistant
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Background : There have been no reports to evaluate the usefulness of combination therapy with
glycopeptide and arbekacin in endocarditis by in vivo model.
Materials and Methods : We investigated the efficacy of the arbekacin and teicoplanin combina-
tion on glycopeptide intermediate Staphylococcus aureus (GISA) in rabbit model of endocardits.
GISA Mu50 strain was used for the experiment. The rabbit model of aortic valve endocarditis as
described previously was used. Treatment was started 20h later inoculation with teicoplanin alone
(at 20 mg/kg of body weight intramuscularly every 12 hours for 4 days after loading dose of 40
mg/kg of body weight intramuscularly), arbekacin alone (5 mg/kg of body weight intramuscularly
every 12h for 4 days), or teicoplanin plus arbekacin.
Results : The results of therapy for experimental endocarditis due to Mu50 showed that teicoplanin
and arbekacin combination was more effective than the administration of both drugs alone in
reducing the log10CFU/g of aortic vegetation (P＜0.05).
Conclusion : The combination of teicoplanin and arbekacin was more effective against GISA
(Mu50) than both drugs alone in vivo endocarditis model.
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subpopulations in a rabbit model of endocarditis.
The benefit of combination therapy with a cell wall
active agents and aminoglycosides has not been defini-
tively established by human clinical trials of S. aureus
infective endocardits. However, Perry et al. (3) recom-
mended that if a glycopeptide is indicated for the treat-
ment of endocarditis, combination therapy with a suitable
aminoglycoside should be considered.
Hanaki et al. (4) reported the synergistic interactions
between arbekacin and teicoplanin against GISA strains.
And, Lee et al. (5) reported that the combinations of
arbekacin with vancomycin, teicoplanin, or ampicillin-
sulbactam showed the synergistic interaction against
hetero-GISA strains. But, no reported study has evaluat-
ed the usefulness of glycopeptide-arbekacin combination
therapy in endocarditis due to GISA using an in vivo
model.
In this study, we investigate the efficacy of teicoplanin
and arbekacin on GISA in a rabbit model of endocarditis.
MATERIALS AND METHODS
1. Strains and animals
Mu50 strain (a gift from Dr. Hiramatsu) was used for
the experiment. MICs were determined by broth micro-
dilution method of the Clinical and Laboratory Standards
Institute (CLSI), formerly the National Committee for
Clinical Laboratory Standards (NCCLS) (6). MIC deter-
minations were performed using cation-adjusted Mueller
-Hinton broth with an inoculums of 5×105 CFU/mL. Two
antimicrobial agents were used in the experiment; tei-
coplanin (Aventis, Seoul) and arbekacin (Meiji Seika, Ltd,
Tokyo, Japan). The experimental animals were 2.5 kg,
white New Zealand rabbits.
2. Experimental staphylococcal endocarditis
To evaluate the efficacy of teicoplanin and arbekacin
on GISA, we used a rabbit model of aortic valve endo-
carditis, which has been described previously (7). The
animals received 50-60 mg of sodium pentobarbital in-
travenously and were anesthetized by ethyl ether in-
halation. The right carotid artery was exposed through a
5 cm longitudinal incision in the neck, ligated and then
incised. A polyethylene catheter was inserted a distance
of about 9 cm until resistance was met. It was then
withdrawn slightly and tied in place. The tip thus re-
mained in a position just above the semilunar cusps of
the aortic valve. The catheter was then filled with a
sterile saline, and the skin incision was closed with silk
over the free end of the catheter. Twenty-four hours
after catheter placement, the rabbits were infected with
107 CFU of S. aureus.
3.Treatmentwithantibiotics andquantitativeculture
The pretreatment burden of the organisms in the ve-
getations was determined using untreated control rabbits,
which were killed 20 hours after inoculation. Treatment
was started 20 hours after inoculation with teicoplanin
alone (at 20 mg/kg of body weight intramuscularly every
12 hours for 4 days after loading dose of 40 mg/kg of
body weight intramuscularly), arbekacin alone (at 5
mg/kg of body weight intramuscularly every 12 hours
for 4 days), or teicoplanin plus arbekacin. The teicoplanin
dose of 20 mg/kg every 12 hours was based on the pre-
vious report that showed a peak and trough concentra-
tion in serum of 44±5 µg/mL and 21±5 µg/mL, respec-
tively (2). The arbekacin dose of 5 mg/kg every 12
hours was based on the previous reports that showed a
1-h postdose concentration in serum of 18 ± 0.46 µg/ml
at 5 mg/kg intramuscularly (8). Treated rabbits were
euthanized 20 hours after the administration of the last
antibiotic dose. Aortic valve vegetations were harvested,
weighed, and homogenized in 0.5 mL of 0.9% saline with
a tissue homogenizer (Wheaton Science, Milleville, NJ,
USA). Serial ten-fold dilutions of the homogenate were
made in 0.9% saline and quantitatively cultured on
Mueller-Hinton agar containing 8 µg of teicoplanin per
ml. These dilutions avoided any significant in vivo
carryover (9). After incubation at 37℃ for 24 hours,
colonies were counted and the results obtained were
expressed in log10CFU per gram of vegetation. The lower
detection limit for this method is 1 CFU per 50 µL of
undiluted vegetation homogenate.
4. Statistical analysis
Comparisons of mean bacterial counts (log10CFU per
Efficacyof Arbekacin/Teicoplanin onGISA Endocarditis Vol.40, No.2, 2008 103
gram of vegetation) between groups were determined by
analysis of variance (one-way ANOVA). Turkey's post
hoc comparison was used. A P value≤0.05 was con-
sidered significant. Statistical analysis was performed
using SPSS 11.0 (SPSS, Chicago, IL, USA).
RESULTS　
The MICs of arbekacin and teicoplanin for M50 strain
were 8 µg/mL and 16 µg/mL.
The results obtained using the 4-days antibiotic treat-
ment regimen, for experimental endocarditis due to GISA
M50, are presented in Table 1. A total of 12 rabbits
infected with GISA M50 were assigned to the control
group (n=3) and to the various treatment regimens
groups (3 for teicoplain alone, 3 for arbekacin alone and
3 for arbekacin/teicoplanin). Control rabbits had a mean
±standard deviation aortic valve vegetation bacterial
count of 8.51±0.67 log10 CFU per gram. Treatment with
arbekacin alone or with teicoplanin alone did not reduce
the aortic valve vegetation bacterial count significantly.
However, treatment with arbekacin/teicoplanin reduced
the aortic valve vegetation bacterial count significantly
(P<0.05).
DISCUSSION
Methicillin-resistant Staphylococcus aureus (MRSA)
has become a major nosocomial pathogen, and commu-
nity-acquired infections caused by MRSA are increasing.
Glycopeptide has been the main antimicrobial agent for
treating severe infections caused by gram-positive bac-
teria, and is used for the treatment of infections caused
by antibiotics-resistant gram-positive bacteria such as
MRSA, and β-lactam resistant enterococci. However,
vancomycin-resistant enterococci and S. aureus strains
with reduced susceptibilities to glycopeptides have emer-
ged (10-12), and the emergence of GISA has raised the
question of the clinical relevance of this low level of
resistance and of the efficacies of glycopeptides for the
treatment of infections due to GISA. However, vanco-
mycin treatment failures and slow clinical responses in
cases of S. aureus endocarditis have been reported (13).
Arbekacin, a derivative of the aminoglycoside dibek-
acin has been used in Japan to treat infections caused by
MRSA. S. aureus resistant to aminoglycoside has been
reported to produce the enzymes 4'-aminoglcoside adenyl-
transferase, 3'-aminoglycoside phosphotransferase, or
2'-aminoglycoside phosphotransferase. However, arbek-
acin has a low modification rate for the several amino-
glycoside-modifying enzymes, so this antibiotic is ex-
pected to be used to treat MRSA infection (14, 15).
Hanaki et al. (4) reported that. there were synergistic
interaction between arbekacin and teicoplanin against
GISA Mu50 strain by checkerboard synergy testing with
fractional inhibitory concentration (FIC) index of 0.375.
Antibiotic combinations for the treatment of endocarditis
should produce a rapid bactericidal effect. In experimen-
tal animals, it has been shown that the rate of bacteri-
cidal action expressed by combination of drugs in broth
is predictive of the relative rate at which the organisms
would be eradicated from the cardiac vegetations in vivo
(16). So, the combination of glycopeptides and arbekacin
could be an alternative option in the treatment of GISA
endocarditis.
This study showed that the treatment with teicoplanin
and arbekacin in combination may be more effective than
treating with either teicoplanin or arbekacin alone in a
rabbit model of endocarditis. This finding is the first
report about the usefulness of glycopeptide-arbekacin
combination therapy in endocarditis due to GISA using
an in vivo model.
Because we used in vivo model for evaluating the
usefulness of combination treatment and the definitions
of synergism in this model have not been defined, we
could not evaluate the synergistic or additive effects of
Table 1. Outcome of 4-days Treatment for Experimental VISA Aortic Valve Endocarditis
Control
(N=3)
Arbekacin alone
(N=3)
Teicoplanin alone
(N=3)
Arbekacin plus Teicoplanin
(N=3)
Mean bacterial count (log10 CFU/g)±SD 8.51±0.67 8.18±0.76 8.37±0.03 5.54±0.41
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the combination treatment. However, we could verify that
the treatment with teicoplanin and arbekacin in com-
bination could significantly decrease the mean bacterial
counts of vegetation by about 3.0 log10 CFU/g.
Although we did not measure the serum levels of the
antimicrobial agents, the peak and trough concentrations
of those agents would be higher than MICs of the agents
for Mu50 strain (2, 8). However, the treatment with
teicoplanin or arbekacin could not decrease the mean
bacterial counts, compared with the control group. The
suboptimal efficacy of those agents may be related to the
maldistribution of the agents within vegetations (17).
And, the bacteria in the vegetations could reach the
large population.
However, there are several limitations in this study.
First, the small number of animals per group were used.
Although there were statistical significance between the
combination therapy group and the single drug group,
this is not a sample size big enough for a study from
which fundamental conclusions are being drawn. Second,
the serum levels of the agents were not measured and
the doses of teicoplanin and arbekacin may have been
lower than the therapeutic doses.
In spite of the limitations, the results of our study
suggests that the combination of glycopeptide and arbe-
kacin may be useful in the treatment of endocarditis
caused by GISA. Further study should be performed
about the effectiveness of glycopeptide and arbekacin
combination.
요 약
목 적: 동 물 모 델 을 이 용 하 여 GISA에 의 한 심 내막 염 에
서 teicoplain과 arbekacin 병 용 요 법 의 치 료 효 과 를 알 아 보
고 자 하 였 다 .
재료 및 방법: 토 끼 심 내막 염 모 델을 이 용 하 여 GISA 에
의 한 심 내막 염 에서 teicoplanin과 arbekacin 병 용 요 법 의 효
과 를 단 독 요 법 의 효 과 와 비 교 하 였 다 . GISA 균 주 는 Mu50
균 주 를 사 용 하 였 고 , 기 존 문 헌 과 동 일 한 방 법 으 로 토 끼 를
이 용 하 여 동 맥판 심 내막 염 모 델을 사 용 하 였 다 . 항 생제 치 료
는 균 을 주 사 한 지 20시 간 이 후 에 시 작 하 였 다 . Teicoplanin
은 40 mg/kg를 1회 근 육 주 사 한 후 에 20 mg/kg의 용 량 을
12시 간 마 다 4일 간 투 여 하 였 다 . Arbekacin은 5 mg/kg를 12
시 간 마 다 4일 간 근 육 주 사 하 였 다 . 마 지 막 항 균 제 투 여 20
시 간 이 후 에 토 끼 대 동 맥판 의 증 식 (vegetation)을 채취 하 였
다 . 항 균 제 를 투 여 하 지 않 은 대조 군 , teicoplanin 단 독 치 료
군 , arbekacin 단 독 치 료 군 , teicoplanin과 arbekacin 병 용
치 료 군 간 의 증 식 의 무 게 (gram) 당 log10CFU의 차 이 를 비
교 하 였 다 .
결 과:Teicoplanin과 arbekacin 병 용 치 료 군 에서 teico-
planin 단 독 치 료 군 , 혹 은 arbekacin 단 독 치 료 군 에 비 해 증
식 의 무 게 (gram)당 log10CFU 값 이 유 의 하 게 낮 았 다 (P
<0.05).
결 론: 동 물 모 델에서 GISA에 의 한 심 내막 염 에 대한
teicoplanin 과 arbekacin 병 용 치 료 의 효 과 가 teicoplanin이
나 arbekacin 단 독 치 료 에 비 해 우 월 하 였 다 .
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